Healthcare provider profile · identity verified

Robert L. Archer, MD

Neurology · LITTLE ROCK, AR · NPI 1699865170

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	417	85
Baclofen	Baclofen	322	79
Tizanidine Hcl	Tizanidine Hcl	211	47
Clonazepam	Clonazepam	167	32
Carbamazepine	Carbamazepine	139	33
Dalfampridine Er	Dalfampridine	138	23
Topiramate	Topiramate	127	25
Methylphenidate Hcl	Methylphenidate Hcl	118	29
Sodium Chloride	0.9 % Sodium Chloride	117	24
Diazepam	Diazepam	112	28
Trazodone Hcl	Trazodone Hcl	105	23
Sertraline Hcl	Sertraline Hcl	102	21
Pregabalin	Pregabalin	101	21
Duloxetine Hcl	Duloxetine Hcl	98	22
Ropinirole Hcl	Ropinirole Hcl	96	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	93	22
Prednisone	Prednisone	89	29
Levetiracetam	Levetiracetam	87	12
Tramadol Hcl	Tramadol Hcl	76	16
Gammaked	Immune Globul G/Gly/Iga Avg 46	71	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	70	17
Bupropion Xl	Bupropion Hcl	69	13
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	67	suppressed
Modafinil	Modafinil	65	16
Glatiramer Acetate	Glatiramer Acetate	60	11
Nortriptyline Hcl	Nortriptyline Hcl	60	suppressed
Teriflunomide	Teriflunomide	60	11
Lorazepam	Lorazepam	58	19
Quetiapine Fumarate	Quetiapine Fumarate	58	11
Fluoxetine Hcl	Fluoxetine Hcl	57	14
Omeprazole	Omeprazole	53	suppressed
Alendronate Sodium	Alendronate Sodium	51	suppressed
Promethazine Hcl	Promethazine Hcl	51	12
Citalopram Hbr	Citalopram Hydrobromide	50	17
Atorvastatin Calcium	Atorvastatin Calcium	48	suppressed
Emgality Pen	Galcanezumab-Gnlm	47	suppressed
Lamotrigine	Lamotrigine	46	12
Copaxone	Glatiramer Acetate	44	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	44	suppressed
Methotrexate	Methotrexate Sodium	41	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	40	12
Doxycycline Hyclate	Doxycycline Hyclate	39	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	39	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	38	suppressed
Methylprednisolone Sodium Succ	Methylprednisolone Sod Succ	38	14
Alprazolam	Alprazolam	36	suppressed
Nurtec Odt	Rimegepant Sulfate	34	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Ibuprofen	Ibuprofen	32	suppressed
Propranolol Hcl	Propranolol Hcl	32	suppressed
Donepezil Hcl	Donepezil Hcl	30	12
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Meloxicam	Meloxicam	28	suppressed
Carbamazepine Er	Carbamazepine	27	suppressed
Losartan Potassium	Losartan Potassium	27	suppressed
Amantadine	Amantadine Hcl	26	suppressed
Famotidine	Famotidine	26	suppressed
Fingolimod	Fingolimod Hcl	26	suppressed
Panzyga	Immun Glob G(Igg)-Ifas/Glycine	26	suppressed
Aimovig Autoinjector	Erenumab-Aooe	25	suppressed
Dimethyl Fumarate	Dimethyl Fumarate	25	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	25	suppressed
Acyclovir	Acyclovir	24	suppressed
Ocrevus	Ocrelizumab	24	13
Pyridostigmine Bromide	Pyridostigmine Bromide	24	suppressed
Tecfidera	Dimethyl Fumarate	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	23	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Verapamil Hcl	Verapamil Hcl	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Fluconazole	Fluconazole	19	suppressed
Ondansetron Hcl	Ondansetron Hcl/Pf	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Kesimpta Pen	Ofatumumab	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Azathioprine	Azathioprine	17	suppressed
Oxcarbazepine	Oxcarbazepine	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Aripiprazole	Aripiprazole	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	14	suppressed
Dexamethasone	Dexamethasone	14	suppressed
Diphenhydramine Hcl	Diphenhydramine Hcl	14	suppressed
Naproxen	Naproxen	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Zonisamide	Zonisamide	14	suppressed
Carisoprodol	Carisoprodol	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	13	suppressed
Metoprolol Succinate	Metoprolol Succinate	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Ultomiris	Ravulizumab-Cwvz	13	suppressed
Azithromycin	Azithromycin	12	suppressed
Desmopressin Acetate	Desmopressin Acetate	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Furosemide	Furosemide	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Amlodipine Besylate	Amlodipine Besylate	11	suppressed
Atovaquone	Atovaquone	11	suppressed
Bafiertam	Monomethyl Fumarate	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Leucovorin Calcium	Leucovorin Calcium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error